**A Multi-Targeted Antisense Oligonucleotide-Based Therapy Directed at Phosphodiesterases 4 and 7 for COPD**

Rosanne Seguin and Nicolay Ferrari *Topigen Pharmaceuticals Inc., Part of the Pharmaxis Ltd. Group, Montréal, QC Canada* 
